Loading
This closed study tested talazoparib in advanced cancers with selected DNA-repair or PTEN alterations. Its published somatic-BRCA results come from a small mixed-cancer cohort.
Registry active not recruiting, last updated 2026-06-12. Advanced cancers with BRCA1/2, selected other DNA-repair or PTEN alterations. The registry enrollment is estimated at 150; the 2024 publication reports 79 treated participants and 18 in the somatic BRCA1/2 cohort. These are different populations, not conflicting efficacy denominators. No current enrollment route.
Shares Talazoparib, PARP, Breast cancer (all types).
Shares PARP, Breast cancer (all types), Triple-negative breast cancer (TNBC).
Shares Talazoparib, PARP, Triple-negative breast cancer (TNBC).
Shares PARP, Breast cancer (all types), Triple-negative breast cancer (TNBC).
Shares PARP, Breast cancer (all types), Triple-negative breast cancer (TNBC).
Shares PARP, Breast cancer (all types).
Shares PARP, Breast cancer (all types).
Shares PARP, Breast cancer (all types), Triple-negative breast cancer (TNBC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/